The phosphatidylinositol-3-kinase (PI3K) pathway is well known to regulate a wide variety of essential cellular functions, including glucose metabolism, translational regulation of protein synthesis, cell proliferation, apoptosis, and survival. Aberrations in the PI3K pathway are among the most frequently observed in cancer, and include amplifications, rearrangements, mutations, and loss of regulators. As a net result of these anomalies, the PI3K pathway is activated in many malignancies, including in Hodgkin and non-Hodgkin lymphomas, and yields a competitive growth and survival advantage, increased metastatic ability, and resistance to conventional therapy. Numerous inhibitors targeting various nodes in the PI3K pathway are undergoing clinical development, and their current status in lymphoma will be the focus of this review.
Introduction
The phosphatidylinositol-3-kinase (PI3K) family consists of a number of serine/threonine and lipid kinases, including those that phosphorylate the membrane-bound phosphatidylinositol-3 (PIP3). These enzymes, and the downstream Akt (also referred to as protein kinase B) and mammalian target of rapamycin (mTOR), have a profound role in multiple critical cellular processes, including growth, differentiation, metabolism, survival, and cellular proliferation ( Fig. 1) . [1] [2] [3] Recently, many novel inhibitors of various portions of the PI3K pathway have entered clinical trials for patients with lymphomas. Because inhibition of this pathway preliminarily appears to be a promising strategy for other malignancies, there is a high degree of interest regarding the current and future therapeutic relevance of the PI3K pathway and lymphoma.
PI3K/Akt/mTOR Pathway Biology
The PI3K enzymes consist of 3 classes with variable primary structure, function, and substrate specificity. Class I PI3Ks, the class most widely implicated as aberrant in cancers, consist of heterodimers of regulatory and catalytic subunits, and are subdivided into 1A and 1B based on their mode of activation (Fig. 1 ).
Class 1A PI3Ks are activated by various cell surface tyrosine kinases, and consist of the catalytic p110 and regulatory p85 subunits. The 3 known isoforms of Class 1A p110 are p110a, p110b, and p110d, which all contain an amino terminal regulatory interacting region (which interfaces with p85), a Ras binding domain, and a carboxy terminal catalytic domain. [3] [4] [5] Class 1B
PI3Ks consist of the catalytic (p110g) and regulatory (p101) subunits and are activated by G-protein coupled receptors. The 4 p110 isoforms have variable tissue distribution and different physiologic functions (Table 1) . [6] [7] [8] [9] [10] [11] p110a is expressed ubiquitously, including leukocytes, is encoded by the frequently mutated gene PIK3CA, and is lethal when removed in embryonic mouse models with decreased proliferation. [12] [13] [14] p110b is also expressed ubiquitously, including leukocytes, and is important in cancer cell motility, insulin signaling, and platelet adhesion. p110b can signal downstream of G-protein coupled receptors, and is also lethal when removed in embryonic mouse models. [15] [16] [17] [18] [19] p110d is expressed in leukocytes, thymus, and breast tissue, and is essential for B-and T-cell development and B-cell receptor signaling. Mouse embryonic knockout of p110d is nonlethal but results in a substantial decrease in B cell number and function. 20, 21 As a result, p110d
is preferentially targeted in B-cell malignancies. p110g is expressed in leukocytes, thymus, cardiac, and endothelial tissue, and is involved in physiologic and pathologic immune function. The nonlethal embryonic knockout mouse model has a severe T cell and neutrophil chemotaxis impairment, with essentially normal B cells. 11, [21] [22] [23] If p110d and p110g are both knocked out, the T cell and natural killer cell populations are significantly diminished in number and function.
Class II and class III PI3K are ubiquitously expressed, are essential for normal cellular function, and do not appear to have an oncogenic function. Class II PI3K consists of 3 classes: PI3K-C2a and PI3K-C2b are ubiquitously expressed and PI3K-C2g is only expressed in hepatocytes. The function of the membrane-bound class II PI3Ks is not yet known, but likely is involved in proteinmembrane lipid interactions. 25 Class III PI3Ks are ubiquitously expressed and essential for survival, as evidenced by the nonviable mouse embryonic knockout model. 26 Class II PI3Ks (a and b isoforms) and class III PI3Ks also play a critical role in the regulation of autophagy. 27 Because class II and III PI3K are essential and are not oncogenic, for clarity, "PI3K" will refer to class I for the remainder of this review. The main product of PI3K is PIP3, the phosphorylated form of membrane-bound phosphoinositides, which initiates a widely active signaling cascade. A main downstream target of PI3K is the serinethreonine kinase Akt, the major oncogenic effector of the PI3K/Akt pathway (Fig. 2) . The primary negative regulator of Akt activation is phosphatase and tensin homolog (PTEN), which functions to dephosphorylate PIP3. 28 Loss of the tumor suppressor PTEN via somatic mutation or epigenetic silencing is a frequent event in many cancers, but uncommon in lymphoma, and allows for increased PI3K signaling. 29 Cell membrane-bound PIP3 allows docking of Akt in proximity to numerous kinase targets, including the mTOR inhibitor tuberous sclerosis complex (TSC)1/2. Additional targets include the oncogenically-relevant MDM2, IKKa, p21, and p27.
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MDM2 promotes cell survival and progression by inhibition of the p53 tumor suppressor, which is reversible by PI3K/Akt inhibition. 31 IKKa is a critical regulator of nuclear factorekB (NFkB) activity, a therapeutically relevant target in many lymphomas, that is activated in part by Akt. 32 Activity of Akt can also inhibit the function of the cell cycle inhibitors p21 and p27, thus leading to unchecked growth. [33] [34] [35] Akt indirectly activates mTOR, a complicated checkpoint of cellular growth influenced by growth factor signaling, adenosine monophosphate levels, and nutrient and O 2 availability. 1 mTOR refers to 2 distinct multimolecular complexes, mTOR complex 1 (mTORC1) and complex 2 (mTORC2). When TSC2 is phosphorylated at Ser939 by activated Akt, it dissociates from TSC1 leading to mTORC1 activation. 36 mTORC1, which activates translational repressor eukaryotic translation initiation factor 4EBP1 and S6K1, is sensitive to rapaymycin-like mTOR inhibitors. 37, 38 mTORC1 activity leads to increased mRNA translation, protein synthesis, and cellular proliferation. mTORC2 is "upstream" from and directly phosphorylates Akt, and is involved in regulation of the cytoskeleton. 39, 40 Demonstrating the complexity of the cross talk found in this pathway, mTORC1 inhibition can lead to activation of the PI3K pathway due to mTORC2 negative feedback, resulting in phosphorylation of Akt. 41 Paradoxically, prolonged mTORC1 inhibition with rapamycin inhibited mTORC2 assembly in approximately 20% of cancer cell lines, and thus resulted in decreased Akt activity.
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PI3K/Akt/mTOR in Lymphoma
Aberrant activation of the PI3K/Akt/mTOR pathway occurs in lymphoma as a result of various anomalies (Fig. 2) . 5, 43 Mutation or gene amplification of the PI3K isoforms can result in increased pathway activity. PIK3CA, the gene encoding p110a, is mutated in < 10% of patients with diffuse large B-cell lymphoma (DLBCL). 44, 45 The provisional data from the cancer genome atlas (TCGA) DLBCL project found no PIK3 mutations in initial available data, although more cases are being studied. 46 In mantle cell lymphoma, mutations of PIK3CA are also rare, but most patients have an increased copy number of PIK3CA, resulting in increased transcription and pathway activation. 47 Mantle cell lymphoma also displays increased p110a expression in relapsed disease, which might be more clinically relevant as a therapeutic PI3K pathway biomarker than p110d. 48 Hodgkin lymphoma displays greater expression of p110d than p110a in preclinical models. 49 A large subset of germinal center Becell-like DLBCL is defined by PTEN loss, which in results in increased PI3K/Akt signaling and in vitro PI3K inhibitor sensitivity. 50 In many cases, PI3K activation might be induced by aberrant signaling from the microenvironment, such as the CD40 ligand. 51 The B-cell receptor (BCR) is a critical signaling pathway for B-cell survival, and is one mechanism of physiologic PI3K pathway activation. BCR-related phosphorylation of the cytoplasmic domain of CD19 provides a docking site for the p85 regulatory subunit of PI3K, which allows for recruitment of the p110 catalytic subunit to the cell membrane. 52, 53 Bruton tyrosine kinase (BTK), an increasingly therapeutically relevant downstream target of BCR signaling, depends on PIP3, and thus PI3K, for membrane binding and activation. 54 Point mutations in the PIP3 binding site of BTK lead to X-linked immunodeficiency and other B-cell deficiencies. Phosphorylation of Akt represents PI3K pathway activation, and is common in lymphomas. Hodgkin lymphoma commonly demonstrates Akt phosphorylation in cell lines and in 63% of patient biopsies. 55 Despite the low rate of PI3KCA mutation in DLBCL, phosphorylation of Akt is common (52%-72% of patient samples) and might be associated with inferior survival. 45, 56 Mantle cell lymphoma demonstrates variable levels of Akt phosphorylation, although the aggressive blastoid subtype appears to require constitutive Akt activation for survival. 57 Peripheral T-cell lymphoma demonstrates phosphorylation of Akt in 49% of cases, which is strongly correlated with inferior clinical outcomes. 58 Aberrant activation of the mTOR signaling network is common in multiple subtypes of lymphoma, due to upstream events and/or nutrient availability. 59, 60 The activity of mTOR often results from the upstream aberrations described, but might also be activated by mTOR-specific biology. In a subset of mantle cell lymphoma, mTOR regulates glycogen synthase kinase (GSK)-3b independently of Akt, and thus controls cyclin D1 regulation. 61 Most DLBCL cell lines and patient samples have overexpression of p70S6K, a downstream target of mTOR. 62 Increased levels of mTOR activity have been found in most Hodgkin lymphomas, and low levels correlated with improved clinical outcomes. 63 
Clinical Trials
PI3K Inhibitors
Inhibitors of PI3K might target specific (eg, p110a) or all (pan class I) isoforms. To date, PI3K inhibitors are not specific for mutant isoforms, and thus also affect wild type PI3K and physiologic PI3K activity. Early versions of pan class I PI3K inhibitors, now commonly used as tool compounds for in vitro study (eg, LY294002 or wortmannin), have significant off-target effects or solubility problems, and thus are not clinically viable drugs. 64 A recent modification to LY294002 has revived its clinical prospects by binding it to a peptide via a cleavable linker, creating the prodrug SF1126. 65 A phase I trial of SF1126 in patients with advanced solid tumors and B-cell malignancies found stable disease in chronic lymphocytic leukemia (CLL) patients (50%; 2/4) and a 40% reduction in lymph node size after 1 cycle in a DLBCL patient. Newer pan class I PI3K inhibitors, such as buparlisib (BKM120), 66 SAR245408, 67 and BAY 80-6946 68 have shown less off-target effects, and generally are well tolerated. A phase I trial evaluating SAR245408 in patients with relapsed lymphomas and CLL found infrequent adverse events including diarrhea, hyperglycemia, headache, and lymphopenia. Preliminary results from early phase trials show broad activity across non hodgkin lymphoma (NHL) subtypes, with an overall response rate (ORR) of 50% in follicular lymphoma (FL), and small lymphocytic lymphoma (SLL)/CLL ( Table 2) . [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] Buparlisib has also been well tolerated, with rash, hyperglycemia, mood alteration, and pruritus reported in < 50% of patients. In a phase I trial in heavily pretreated solid tumor patients, 1 patient achieved a partial response and 16 patients (52%) achieved stable disease. 66 Of note, 5 of the 7 patients who continued participation in the trial for > 8 months had documented genomic aberrations in the PI3K pathway, perhaps allowing for future biomarker-based trials. An international phase II trial of buparlisib in relapsed DLBCL, mantle cell lymphoma, and FL has opened and accrual is expected to complete in 2014. In trials of BAY 80-6946, an inhibitor of primarily the PI3K-d and PI3K-a isoforms, investigators have found toxicities similar to other pan class I PI3K inhibitors and promising response data in patients with relapsed indolent NHL. 68, 71 PI3K inhibitors with activity against specific isoforms include idelalisib (formerly CAL-101 and GS-1101, p110d) and IPI-145 (p110d and p110g) ( Table 2) . [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] Idelalisib activity has been examined in a variety of B-cell malignancies. A phase I trial of idelalisib showed minimal toxicities, and ORR of 67% in relapsed indolent lymphomas. 72 Based on these data, idelalisib was evaluated in combination with rituximab, bendamustine, or both in patients with relapsed indolent lymphoma. 85 No major added toxicities were seen, and the ORRs were 77%, 85%, and 77% for the idelalisib and rituximab, idelalisib and bendamustine, and idelalisib and rituximab and bendamustine treatment groups. The progression-free survival at 20 months for all patients and responders was 66% and 73%, respectively, and randomized phase III trials are planned. 86 Preliminary results from a phase I trial of idelalisib with everolimus, bortezomib, or bendamustine and rituximab in relapsed mantle cell lymphoma showed similar mild toxicity and questionable enhanced clinical responses. 87 IPI-145 targets p110d and p110g, and therefore might have activity in B-and T-cell malignancies. At the 2013 American Society of Clinical Oncology Annual Meeting, an interim update demonstrated the efficacy of IPI-145 in T-cell (ORR, 33%) and B-cell lymphomas (ORR, 52%). 77 Preliminary toxicity data appear mild and similar to other PI3K inhibitors, however significant infectious complications have occurred and prophylactic antibiotic, antiviral, and antipneumocystis medications are recommended. 84 These infections are likely due to the activity of the drug on the benign immune cells, representing an undesired "on target" effect. Rigosertib, a multikinase inhibitor, induces reactive oxygen species and directly inhibits PI3K, with preferential activity against the p110a and p110b isoforms. In a phase I trial of rigosertib (formerly ON 01910.Na) in relapsed hematologic malignancies, investigators found mild toxicity and stable disease in 54% (7/13) of evaluable patients, though no clinical responses were observed. 78 A phase III trial is under way for myelodysplastic syndrome, and further development in lymphoma would likely require combination therapy or alternate scheduling.
A new generation of PI3K inhibitors that inhibit wild type and mutant class I isoforms are in early phase clinical trials. BYL719, an inhibitor specific for PIK3CA wild type and mutant p110a, has shown favorable safety and interesting efficacy in solid tumors and further trials are planned. 88 
Akt Inhibitors
Perifosine is a first-generation Akt inhibitor that functions via inhibition of Akt translocation to the cell membrane. 89 Combined in a phase II trial with the multikinase inhibitor sorafenib, perifosine had an ORR of 28% in relapsed Hodgkin lymphoma. 90 In this trial, the reduction of phosphorylated extracellular signal regulated kinases (p-ERK) and pAKT values at day 60 strongly correlated with response, although it is not clear if basal differences could be used for patient selection as predictive biomarkers. Due to mild efficacy and moderate toxicities, there are currently no ongoing clinical trials evaluating perifosine in patients with lymphoma. A second-generation Akt inhibitor, MK-2206, functions via allosteric Akt inhibition and has shown strong preclinical activity in a variety of lymphoma cell lines and patient samples. 91 In a phase I trial in patients with relapsed solid tumors, investigators found rash and gastrointestinal complaints to be common, but manageable. 92 Several clinical trials evaluating MK-2206 in patients with relapsed lymphoma are ongoing.
mTOR Inhibitors
Rapamycin-like inhibitors, often referred to as "rapalogs," have moderate activity in lymphoma by allosterically inhibiting mTORC1 (Table 2 ). Temsirolimus has significant activity in relapsed mantle cell lymphoma, alone (ORR of 38%) 82 and with rituximab (ORR of 59%). 93 Based on these data, temsirolimus has received orphan drug approval for relapsed mantle cell lymphoma in Europe. Temsirolimus has efficacy in other NHL subtypes, including follicular, SLL, and aggressive lymphomas. 83 Newer rapalogs, such everolimus, are currently being evaluated in relapsed lymphoma. Everolimus is an oral mTORC1 inhibitor that is approved by the Food and Drug Administration for relapsed renal cell, brain, neuroendocrine, and hormone receptor-positive breast cancers. A phase II trial of everolimus in relapsed aggressive lymphoma showed mild toxicities and an ORR of 30%, including 30% of patients with relapsed DLBCL. 79 In heavily pretreated Hodgkin lymphoma, everolimus was well tolerated and resulted in a 42% ORR and 35% stable disease rate. 80 When combined with sorafenib in a phase I trial treating relapsed lymphoma and multiple myeloma, everolimus demonstrated modest toxicity and an ORR of 33%, including 5 of 6 Hodgkin lymphoma patients. 94 Based on these data and preclinical studies, everolimus was also evaluated in combination with the histone deacetylase inhibitor panobinostat in 2 separate clinical trials in lymphomas and multiple myeloma. 93, 95, 96 Toxicities were mild and the ORR was 33% to 43% in heavily pretreated lymphoma and myeloma patients, with most lymphoma patients achieving some degree of tumor regression. 97 Everolimus has also been combined with conventional chemotherapy (CHOP) in T-cell lymphomas in a small phase I trial with acceptable toxicity and impressive efficacy. 98 A newer generation of mTOR inhibitors, which are now entering clinical trials, are able to block mTORC1 and mTORC2, and might allow greater efficacy and avoidance of the compensatory phosphorylation of Akt.
Predictive Biomarkers
As our understanding of cancer biology and mechanisms of drug efficacy improve, so does our ability to categorize patients that are more likely to benefit from a particular therapy. Pharmacoprognostic markers are not yet robust enough for patient selection in PI3K/Akt/mTOR pathway clinical trials in lymphoma, but do show potential. In a small clinical trial evaluating the Akt inhibitor perifosine and multikinase inhibitor sorafenib, baseline levels of phosphorylated Akt and ERK in peripheral lymphocytes correlated with therapeutic response. 99 In an elegant cell line screen of PI3K 104, 105 Eventually, these early approaches at therapeutic response predication should allow oncologists to personalize therapy for patients with PI3K/Akt/ mTOR-driven cancers, including lymphomas. 106 A challenge that will arise using sequencing and/or proteomics to personalize therapy for Hodgkin lymphoma will be to overcome the relatively low malignant cellularity in biopsy samples. Special techniques will be required to isolate the rare malignant cells to avoid the majority of the data to originate from benign infiltrating immune cells.
Conclusions
The PI3K/Akt/mTOR pathway is known to be important and has been successfully targeted in many cancers, including many lymphomas. Targetable aberrations along the entire course of the pathway have been observed, however, none of the histologically defined lymphoma subtypes appear to be driven primarily by PI3K/ Akt/mTOR. Development of potent inhibitors with specificity for mutant isoforms of PI3K, and rational combination strategies might limit toxicity and improve efficacy. As seen with targeted inhibitors in other cancer patient populations, the efficacy of small molecule inhibitors as single agents for patients with lymphomas might be limited, and long-term disease control might be rare. 107 Therefore, it is likely that rationally designed combination clinical trials will be needed to target either multiple "nodes" of the PI3K/Akt/mTOR pathway simultaneously, or to cotarget accessory pathways to overcome resistance mechanisms. The success of future trials will depend on the ability of investigators to define populations with dependence on PI3K/Akt/mTOR aberrations, and to optimally target these aberrations.
Clinical Practice Points
The PI3K/Akt/mTOR pathway is essential to the growth, differentiation, metabolism, survival, and cellular proliferation of lymphomas. Activation of the PI3K pathway occurs from multiple genomic aberrations, and no lymphoma subtypes are thought to be primarily "PI3K-driven." p110d is essential for B-cell development and BCR signaling, and is thus primarily targeted in B-cell malignancies. p110g is involved in physiologic immune function, and thus "on target" toxicities might include opportunistic infections. mTOR inhibitors have shown moderate activity across a wide range lymphoma subtypes, but might in turn lead to Akt activation via a feedback loop. Predictive biomarkers will prove essential to eventually select lymphoma patients most likely to benefit from PI3K pathway inhibition.
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